Despite mounting frustrations in drug R&D for Alzheimer's disease, emerging biopharma firms are still pursuing AD therapies with new science, and different preclinical and clinical trial models.
Alexander Neumeister
Advertisement
Articles by Alexander Neumeister
Advertisement
Latest Updated Articles
Alzheimer’s Research Finds New BeginningsPublished: October 1st 2019 | Updated:
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
